Topic: Parkinson's disease
When doctors first diagnose Parkinson’s patients, their main focus is motor control. And that gives Acadia, maker of Nuplazid, a big job to do.
Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
Acorda has pulled off a crucial approval for Parkinson’s drug Inbrija, but that doesn’t mean the company is out of the woods.
With an FDA safety review in the rearview mirror, Acadia is back to business on Nuplazid—and launching its first branded ad campaign to boot.
UCB's new mobile app is built specifically for Parkinson’s disease with a virtual health assistant named April.
Manufacturing issues at a CMO and a missed forecast by Merck have led to a shortage of some of its Parkinson’s disease drug Sinemet.
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
Intec Pharma is partnering with LTS Lohmann Therapie-Systeme to manufacture its lead drug candidate Accordion Pill carbidopa/levodopa, designed to treat severe symptoms in advanced cases of Parkinson’s disease.
Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.